Announcements Trials
Browse Landscape

Phase

Phase NA 7Phase 2/3 1Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Uveal Melanoma 1Retinal Diseases 1Melanoma 1Macular Degeneration 1Choroid Diseases 1

Interventions

Cisplatin 98Gemcitabine 66Paclitaxel 62Carboplatin 60Fluorouracil 59Docetaxel 59Capecitabine 59Oxaliplatin 56Cyclophosphamide 54Radiotherapy 50Drug Therapy 46Bevacizumab 38pembrolizumab 35Dexamethasone 33Magnetic Resonance Spectroscopy 32Leucovorin 32Doxorubicin 31Cytarabine 27Etoposide 26Pemetrexed 25Nivolumab 24Methotrexate 24Radiation 20Vincristine 18venetoclax 17apatinib 17Rituximab 17Prednisone 17Letrozole 17Irinotecan 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × salicylhydroxamic acid × Clear all
NCT00811200 2009-07-02

TORR

Leiden University Medical Center

Phase 2/3 Unknown
220 enrolled
Dermatologic

Uveal Melanoma, Macular Degeneration, Melanoma, Retinal Diseases, Choroid Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡